December 8, 2025
Oblong, Inc. Announces Corporate Name Change to TaoWeave, Inc.
Company officially changes corporate name to TaoWeave, Inc., reflecting its evolution into a digital asset treasury company.
Read More →Leadership
The team driving TaoWeave's strategic vision.
Executive Team
Peter Holst
Chief Executive Officer
Pete brings over 25 years of technology industry leadership to TaoWeave. As CEO, he is spearheading the company's strategic transformation into a digital asset treasury company focused on Bittensor (TAO). His career spans executive roles across high-growth technology and communications companies, including serving as President and COO of Raindance Communications, where he led the company through a successful sale to West Corporation. Pete has a proven track record of building shareholder value, navigating complex market transitions, and executing strategic initiatives in public company environments.
David Clark
Chief Financial Officer
David leads TaoWeave's financial operations, investor relations, and treasury management, including oversight of the company's digital asset holdings and SEC reporting requirements. He brings extensive public company finance experience, having previously served as Vice President of Finance, Treasurer, and acting CFO at Allos Therapeutics, a publicly traded biopharmaceutical company. David began his career with seven years in the audit practice at PricewaterhouseCoopers LLP. He is an active Certified Public Accountant and holds a Master of Accountancy and B.S. in Accounting from the University of Denver.
Board of Directors
Jonathan Schechter
Chairman of the Board
Mr. Schechter joined the Board in May 2023 and has served as Chairman since December 2024. He is a partner at The Special Equities Group, a division of Dawson James Securities, Inc., specializing in healthcare, biotechnology, technology, and clean-tech sectors. He is a founding partner of The Special Equities Opportunity Fund, a long-only fund investing in micro-cap companies. Mr. Schechter serves on the Board of PharmaCyte Biotech, Inc. (Nasdaq: PMCB) and previously served as a director of TAO Synergies Inc. (Nasdaq: TAOX) and DropCar, Inc. He holds an A.B. in Public Policy/Political Science from Duke University and a J.D. from Fordham University School of Law.
Deborah Meredith
Independent Director
Ms. Meredith joined the Board in August 2021. She serves as a board member, advisor, and consultant to several high-tech companies with extensive experience in strategic roles at privately-held startups including Proofpoint, Aviatrix, Qventus, Alation, and Kinsa Health. With more than three decades of experience, she has worked hands-on with company founders to assemble world-class teams, architect software products, and establish operational roadmaps. Ms. Meredith holds a master's degree in computer science from Stanford University and undergraduate degrees in computer science and mathematics from the University of Michigan.
Jason Adelman
Independent Director
Mr. Adelman joined the Board in July 2019. He is the Founder and Managing Member of Burnham Hill Capital Group, LLC, a privately held financial advisory firm, and serves as Managing Member of Cipher Capital Partners LLC, a private investment fund. He also serves on the board of Trio-Tech International (Nasdaq: TRT). Prior to founding Burnham Hill Capital Group in 2003, Mr. Adelman served as Managing Director of Investment Banking at H.C. Wainwright and Co., Inc. He holds a B.A. in Economics, cum laude, from the University of Pennsylvania and a J.D. from Cornell Law School.